Objectives: To develop and validate criteria for the retrospective diagnoses of hypertensive disorders of pregnancy that would be amenable to the development of an electronic algorithm, and to compare the accuracy of diagnoses based on both the algorithm and diagnostic codes with the gold standard, of physician-made diagnoses based on a detailed review of medical records using accepted clinical criteria. Patients and Methods: An algorithm for hypertensive disorders of pregnancy was developed by first defining a set of criteria for retrospective diagnoses, which included relevant clinical variables and diagnosis of hypertension that required blood pressure elevations in greater than 50% of readings ("the 50% rule"). The algorithm was validated using the Rochester Epidemiology Project (Rochester, Minnesota). A stratified random sample of pregnancies and deliveries between January 1, 1976, and December 31, 1982, with the algorithm-based diagnoses was generated for review and physician-made diagnoses (normotensive, gestational hypertension, and preeclampsia), which served as the gold standard; the targeted cohort size for analysis was 25 per diagnosis category according to the gold standard. Agreements between (1) algorithmbased diagnoses and (2) diagnostic codes and the gold standard were analyzed. Results: Sensitivities of the algorithm for 25 normotensive pregnancies, 25 with gestational hypertension, and 25 with preeclampsia were 100%, 88%, and 100%, respectively, and specificities were 94%, 100%, and 100%, respectively. Diagnostic code sensitivities were 96% for normotensive pregnancies, 32% for gestational hypertension, and 96% for preeclampsia, and specificities were 78%, 96%, and 88%, respectively. Conclusion: The electronic diagnostic algorithm was highly sensitive and specific in identifying and classifying hypertensive disorders of pregnancy and was superior to diagnostic codes.
L
arge epidemiological studies assessing the associations among hypertensive disorders of pregnancy (HDPs) and long-term outcomes of mothers and their offspring depend on the accurate determination of the diagnoses of gestational hypertension, preeclampsia, and eclampsia. Medical chart review, coupled with the use of the American College of Obstetrics and Gynecology (ACOG) diagnostic criteria, 1,2 is often considered the gold standard for making retrospective HDPs diagnoses. [3] [4] [5] [6] However, this approach is costly and labor intensive, commonly requiring a time commitment that may be overwhelming to impossible for practicing physicians and thus not feasible for use in large studies. Consequently, the most common strategies include using discharge data from the International Classification of Diseases (ICD), the Hospital International Classification of Diseases Adapted (HICDA) codes, registries, and maternal recall. [7] [8] [9] [10] [11] [12] [13] Diagnostic and administrative billing codes are valuable tools to classify large numbers of patients according to specific diagnoses and to assess patient outcomes in a relatively low-cost and efficient manner. However, there has been increasing concern about the validity of such an approach, especially for research purposes, as some codes have been found to correlate poorly with the true presence or absence of diseases, including HDPs. One notable example is a study of 3084 women from the Danish National Hospital Discharge Register who delivered between 1998 and 2000, which reported a 3.27% incidence of HDPs on the basis of codes vs a 5.86% incidence according to the gold standard consisting of chart review and accepted clinical criteria. 14 The difference in the incidence rates between these 2 approaches was largely due to underestimation of gestational hypertension by codes in the register. A study from Australia 15 reported numerous errors in 2 standard data collection systems compared with an HDPs-specific database that served as a gold standard: up to two-thirds of medical records were coded incorrectly with respect to HDPs. Taken together, published studies indicate that diagnostic codes are not accurate in identifying forms of HDPs other than preeclampsia and, that in women with preeclampsia, the accuracy of codes depends on the severity of the disease. 4 The limitations of the codes may have substantial implications for studies of long-term cardiovascular outcomes after the affected pregnancies, as major differences in clinical presentations and underlying vascular abnormalities among pregnancies with chronic hypertension, preeclampsia, and gestational hypertension may have varying implications for cardiovascular disease later in life. Therefore, large epidemiological studies using HDPs diagnostic codes may have limited abilities to identify differential long-term effects of different HDPs. Consequently, going back to the gold standard, despite its laborious and costly chart reviews, has been proposed as a means to ensure accurate diagnoses. 4 Individual chart review, despite being more sensitive than ICD codes, registries, and maternal recall, commonly requires a time commitment that may be overwhelming to impossible for practicing physicians and thus not feasible for use in large studies. Furthermore, as several medical professionals may be required to evaluate large cohorts, personal biases may be introduced into the chart reviews by individual medical experts. There is therefore a need to develop an accurate and standardized electronic tool to confirm HDPs using retrospective data acquired by trained abstractors other than physicians. This tool will facilitate large epidemiological studies of HDPs outcomes, such as the present study using the Rochester Epidemiology Project (REP), which aims to study long-term cardiovascular outcomes of HDPs in women who delivered between January 1, 1976, and December 31, 1982 (either live births or stillbirths) while residing in Olmsted County, Minnesota.
The objective of this study was to develop an electronic algorithm that can be applied to data obtained from medical records by trained abstractors to diagnose and classify HDPs. In addition, we aimed to compare diagnoses based on the algorithm or diagnostic codes with the gold standard, namely, physicianmade diagnoses based on a detailed review of medical records using accepted clinical criteria.
PATIENTS AND METHODS

Establishment of a Historical Cohort
The REP medical records linkage system 16 was used to establish a cohort of all women with research authorization who delivered at more than 20 weeks between January 1, 1976, and December 31, 1982, while residing in Olmsted County (N¼7794). Furthermore, all women were required to have at least 1 blood pressure (BP) measurement available at both a prenatal visit and hospital admission for delivery, yielding a final cohort of 7544 women. The time period of January 1, 1976, through December 31, 1982, was specifically selected to study longterm outcomes in patients with HDPs.
The REP was created in 1966 to link all health care information from all medical providers for the entire population of Olmsted County. This database is comprehensive, as only 2% of the county residents have denied access to their medical records for research purposes. The REP now includes approximately 6.3 million person-years of patient contact.
Data Abstraction
Data on all pregnancies in women in the cohort with diagnostic codes indicative of a possible HDP between January 1, 1976 and December 31, 1982 were abstracted. During this time period, diagnoses were coded using the Eighth Revision of HICDA coding system, which were not used for billing purposes. The codes used were hypertension (malignant, acquired), preeclampsia, eclampsia, toxemia, hyperreflexia, high BP, and labile BP (these codes are listed in Supplemental Appendix 1, available online at http://www.mayoclinicproceedings.org). The medical records of pregnancies not assigned a diagnostic code of interest were screened for evidence of 2 elevated BPs (systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg) at any point during the pregnancy or at delivery. Charts were abstracted if these criteria were met. Women with pregnancies without any evidence of hypertension were classified as normotensive.
A team of experts assembled from the specialties of obstetrics, maternal-fetal medicine, nephrology and hypertension, epidemiology, and statistics reached a consensus on the relevant clinical variables that needed to be abstracted for confirmation of HDPs and related risk factors. Data abstracted included every outpatient BP reading; the highest and lowest BPs for each calendar day of an inpatient stay; all laboratory data including proteinuria, liver function tests, creatinine level, and platelet count; subjective symptoms of persistent headaches, visual changes, or epigastric pain; hyperreflexia; use of magnesium for seizure prophylaxis; seizures in the hospital or changes in mental status/comatose status; witnessed seizures as an outpatient; and use of antihypertensive medications (Supplemental Appendix 1 contains the full list of abstracted variables). All data were entered into an electronic database by chart abstractors. Data obtained by the abstractors were periodically compared with those obtained by a gold standard reviewer to ensure quality.
Retrospective Diagnosis of Hypertension in Pregnancy: "The 50% Rule" A critical step in the development of the algorithm was making a diagnosis of hypertension in a retrospective manner. The time line and trajectory of BP elevations were taken into account with the goal of simulating clinical judgment (Figure 1 ). We developed a strict definition of hypertension that required sustained hypertension, defined as BP elevations in greater than 50% of readings, starting with the first BP greater than 140 mm Hg systolic and/or greater than 90 mm Hg diastolic ("the 50% rule"), as shown in Figure 1 . We found that the use of 2 BPs greater than 140/90 mm Hg on 2 occasions, at least 4 hours apart, which is part of the ACOG definition of gestational hypertension at the time of clinical disease, is not suitable for making retrospective diagnoses for research purposes (Figure 1 ).
Isolated but nonsustained BP elevations were not taken into account when developing the diagnostic criteria for HDPs, such as those occurring due to medications that can raise BP (eg, methylergonovine maleate, nonsteroidal anti-inflammatory drugs), pain, tobacco, or during emergency department visits. In addition, isolated BP elevations observed only within 24 hours of delivery were not considered diagnostic of gestational hypertension or preeclampsia in the absence of other clinical signs and symptoms.
There were several historical patterns of outdated clinical practice noted in the medical records that also informed the details of the algorithm design. Most notably, some prenatal records, especially from the 1970s and 1980s, registered BPs graphically as dots on a chart, instead of capturing actual numbers, resulting in an overrepresentation of BPs of exactly 140 mm Hg systolic and 90 mm Hg diastolic. It is well established that there is a tendency to round BP readings to the nearest 5 mm Hg. 17 We therefore used BPs strictly greater than 140 mm Hg systolic and greater than 90 mm Hg diastolic to eliminate false positives. Each pregnancy was classified according to BP criteria and abstracted clinical data by using the HDPs algorithm, as described below.
Hypertensive Disorders of Pregnancy Algorithm
We developed an algorithm for the diagnoses of HDPs by first defining the criteria for their retrospective diagnoses of HDPs. These definitions were amenable to the development of an electronic algorithm that classified pregnancies into normotensive; gestational hypertension; preeclampsia-definitive, -probable, or -possible; preeclampsia superimposed on chronic hypertension-definitive, -probable, or- Hypertensive ≤50% 2 FIGURE 1. Diagnosis of hypertension in pregnancy: the time line and trajectory of blood pressure (BP) elevations ("the 50% rule"). The definition of hypertension in pregnancy required sustained hypertension, defined as BP elevations in >50% of readings, starting with the first BP >140 mm Hg systolic and/or >90 mm Hg diastolic ("the 50% rule") (panels A and B, pregnancy 2). Pregnancy 1 in panel B illustrates why sustained elevations in BP are important to confirm the diagnosis of gestational hypertension. For a prenatal visit at 36 weeks, a patient presents with a BP of 142/76 mm Hg after rushing from the parking lot to her appointment. The measurement is repeated, giving a value of 134/68 mm Hg. All previous BP readings were normal. She presents to the clinic at 40 weeks complaining of painful contractions, with a BP of 136/92 mm Hg. Her cervix is dilated to 6 cm, and she is transferred to the labor and delivery department. All subsequent BP readings are normal, and her urine and blood test results are negative for any abnormalities. She has 1 BP of 144/72 mm Hg just before epidural administration. The remaining blood pressures recorded during delivery and postpartum are all less than 140/90 mm Hg. The application of diagnostic criteria that require only 2 BP elevations more than 4 hours apart may categorize this woman as having gestational hypertension, but most clinicians would not agree with this diagnosis.
used when the overall clinical presentations were highly suggestive and indicative of these disorders, respectively, but making definitive diagnoses was not always possible because of suboptimal clinical data related to BP trends and assessments of proteinuria. Figure 2 illustrates a flowchart detailing the criteria used for each algorithm-based diagnosis (for definitions, see Table 1 ).
For patients who were coded as normotensive but experienced BP elevations at 48 and/ or 72 hours postpartum, one of the experts reviewed abstracted data to confirm or rule out diagnoses of gestational hypertension and preeclampsia.
The algorithm was programmed jointly by a study statistician (L.E.V.) and our coinvestigators from the University of Belgrade, Belgrade, Serbia (M.S. and N.M.M.). It is available from http://statistika.mfub.bg.ac. rs/hpd-algorithm/. (Note: For demonstration purposes, please use "test" for login and "dataset" for password. To review test patients, please enter the numbers from 001 to 009 in the "search patients" tab.)
Establishment of the Gold Standard by Physician Chart Review
A stratified random sample of pregnancies with the algorithm-based diagnoses of normotensive pregnancy, gestational hypertension, or preeclampsia was generated from the entire population-based cohort by a project statistician (L.E.V.). The medical records of these a. >50% of all BP readings after 20 gestational weeks were SBP >140 mm Hg and/or DBP >90 mm Hg from the first documented elevation in BP before the admission for delivery onward up to 24 h postpartum OR b. 1 SBP >140 mm Hg and/or DBP >90 mm Hg in a patient who was also taking an antihypertensive medication within 1 wk of high BP after 20 gestational weeks and up to 24 h postpartum c For patients with a single BP elevation at 48 and 72 h postpartum who were coded as normotensive, one of the experts should review abstracted data to confirm or rule out diagnoses of postpartum gestational hypertension and preeclampsia.
Preeclampsia-definitive was confirmed in the presence of hypertension after 20 gestational weeks (as diagnosed above)
plus one of the following:
New-onset proteinuria, defined in patients without preexisting proteinuria (defined as proteinuria or a protein/ osmolality ratio of >0.300 g/24 h, 2 dipsticks of 1þ protein, or 1 dipstick of 2þ protein in <20 gestational weeks) as 1 or more of the following: i. Urinary total protein level >0.300 g/24 h OR a protein/osmolality ratio of >0.300 g/24 h between 3 wk before delivery and up to 72 h after delivery ii. Urinary protein measurement of 2þ protein between 3 wk before delivery and up to 72 h after delivery iii. Urinary protein measurement of 1þ protein at admission for delivery or up to 72 h after delivery iv. If no urinary protein measurement taken throughout admission for delivery and up to 24 h postpartum, then dipstick of 1þ on the prenatal visit closest to the date up to 3 wks before delivery b. Worsening proteinuria, defined in patients with chronic proteinuria (defined as proteinuria or a protein/osmolality ratio of >0.300 g/24 h, 2 dipsticks of 1þ protein, or 1 dipstick of 2þ protein in <20 gestational weeks) as 1 or more of the following: i. Doubling of 24-h urine protein level or protein/osmolality ratio between 3 wk before delivery and up to 72 h after delivery compared with values obtained in <20 wk before pregnancy ii. Increase in baseline dipstick value in <20 wk (1þ / 2þ or 2þ / 3þ) between 3 wk before delivery and up to 72 h after delivery
In patients who either did not have proteinuria or did not have it measured, and consistent with the most recent guidelines that eliminate the dependence of that diagnosis of preeclampsia on proteinuria, the diagnosis was confirmed on the basis of any of the following: e Abnormal laboratory measurements:
2. Serum alanine aminotransferase or aspartate aminotransferase level >70 U/L (to convert to ukat/L, multiply by 0.0167) between 3 wk before delivery and up to 72 h after delivery 3. Platelet count <100,000 Â 10(9)/L if it is the first laboratory test value that is <150,000 Â 10(9)/L between 3 wk before delivery or up to 72 h after delivery 4. Serum creatinine level >1.1 mg/dL (to convert to mmol/L, multiply by 0.0259) or its doubling in the absence of a history of renal disease between 3 wk before delivery and up to 72 h after delivery 5. women were then reviewed independently by 2 obstetricians who were blinded to the algorithm-based diagnoses. Each pregnancy was assigned 1 of 3 exposure statuses (normotensive, gestational hypertension, or preeclampsia) on the basis of their professional opinions and using the ACOG Task Force criteria. 2 If consensus was not reached after 2 physicians reviewed a chart, a strategy was designed for a third physician to review the chart and the exposure status was classified on the basis of majority opinion. This was not required, however, as there was 100% consensus between the first 2 reviewers. This process continued until data on 25 pregnancies of each exposure status (75 women in total), based on physician review, were obtained.
Contemporary Validation Cohort
To validate the algorithm in the present time frame, we tested its performance characteristics using obstetric records of Olmsted County residents with research authorization who delivered at our institution in the time period of January 1, 2012 through December 31, 2015. A stratified random sample of pregnancies with an ICD, Ninth Revision or ICD, 10th Revision billing diagnostic code for gestational hypertension or preeclampsia, and pregnancies without any diagnostic codes suggestive of HDPs, was generated in the above time 
Statistical Analyses
Separate analyses were performed using the set of 75 pregnancies from the historical cohort (1976) (1977) (1978) (1979) (1980) (1981) (1982) and the set of 75 pregnancies from the contemporary validation cohort (2012-2015). Sensitivities and specificities of (1) our algorithm-based diagnoses of HDPs (normotensive, gestational hypertension, and preeclampsia) and (2) code-based diagnoses were calculated with respect to the gold standard (ie, physician review), and 95% CIs were calculated using the exact method. The code-based diagnoses were determined by considering all diagnostic codes within 10 months before and 2 months after each delivery date. Table 2 summarizes the demographic characteristics of the 75 patients identified from the historical cohort. On average, patients had 11.3, 13.9, and 14.6 BP measurements and 8.1, 10.2, and 9.4 dipstick proteins recorded during prenatal visits that were used for analyses in the normotensive, gestational hypertension, and preeclampsia groups, respectively. The gold standard of physician-made diagnoses of normotensive, gestational hypertension, and preeclampsia (n ¼ 25 each) were compared with the diagnoses made using the electronic algorithm. Table 3 presents the detailed results of the algorithm-based diagnoses compared with the gold standard (physician-made diagnoses). Sensitivities (with 95% CIs) for normal pregnancies, gestational hypertension, and preeclampsia were 100% (86%-100%), 88% (69%-98%), and 100% (86%-100%), respectively, and specificities were 94% (84%-99%), 100% (93%-100%), and 100% (93%-100%), respectively. Our algorithm misclassified only 3 gestational hypertensive pregnancies as being normotensive. In all 3 cases, they were misclassified because the number of BPs above the normal range did not meet the 50% rule (where >50% of all BP readings after the first BP elevation were above the normal range). In addition, there were 2 women who were initially coded as normotensive by using the algorithm but elevated BPs were recorded postpartum. As per the algorithm, physician review was requested, leading to the diagnosis of gestational hypertension. The same clinical information was available to coders at the time of HDPs diagnoses and to data abstractors (information used for algorithm-based diagnosis) and physicians (gold standard) at the time of the present study. Compared with the gold standard of physician-made diagnoses, the HICDA code sensitivities (with 95% CIs) were 96% (80%-100%) for normotensive pregnancies, 32% (15%-54%) for gestational hypertension, and 96% (80%-100%) for preeclampsia. Specificities for normotensive pregnancies, gestational hypertension, and preeclampsia were 78% (64%-89%), 96% (86%-100%), and 88% (76%-96%), respectively (Table 3) . Table 4 summarizes the demographic characteristics of the 75 patients in the contemporary cohort. Sensitivities of the algorithm for 25 normotensive pregnancies, 25 gestational hypertension, and 25 preeclampsia were 100% (86%-100%), 76% (55%-91%), and 80% (59%-93%), respectively, and specificities were 80% (66%-99%), 100% (93%-100%), and 98% (90%-100%), respectively. Diagnostic code sensitivities were 68% (47%-85%) for normotensive pregnancies, 100% (86%-100%) for gestational hypertension, and 100% (86%-100%) for preeclampsia, and specificities were 100% (93%-100%), 86% (73%-94%), and 98% (89%-100%), respectively (Table 5) .
RESULTS
Historical Cohort
Contemporary Cohort
DISCUSSION
The goal of this study was to develop and validate an electronic algorithm that uses chartabstracted clinical data for the diagnoses and classification of HDPs. This method exhibited excellent agreement with the physician-made HDPs diagnoses based on re-review of the records and the use of accepted diagnostic criteria. It exhibited greater sensitivity compared with diagnostic codes for the detection of exposure status. Both the sensitivity and the specificity of this approach were superior to those reported in the literature for ICD codes and maternal recall. 4, 14, 18, 19 In particular, the algorithm was more accurate in identifying pregnancies with gestational hypertension. It achieved the accuracy and nuance of physician review while retaining the large-scale applicability of computerbased methods.
Our algorithm seeks to analyze clinical data so that an algorithm-confirmed diagnosis meets the clinical definition of HDPs, but also maximizes specificity by simulating clinical judgment. The algorithm, therefore, is not simply the application of ACOG clinical criteria to a set of chart-abstracted patient data. Indeed, research and clinical definitions of disease may differ. 20 For example, when choosing criteria for the clinical diagnosis of preeclampsia, clinical guidelines have established a minimum threshold designed for maximum sensitivity such that they capture all potential cases. A clinician will use an isolated BP elevation as a prompt for a thorough evaluation and will then either confirm or rule out the diagnosis. In contrast, a research definition should try to be as specific as possible so that only cases that are classic for the disease in question are included. The blanket application of the ACOG criteria outside of a clinical context would result in substantial overinclusion of cases that are not truly positive for preeclampsia. For research purposes, such misclassification may obscure any true 21 The clinical relevance of this approach is obvious: recognition of specific subtypes based on clinical and laboratory information will inform targeted, predictive, preventive, and treatment strategies. To that end, the minimum requirements of clinical data that are sufficient to make retrospective HDPs diagnoses have been reported. We further developed this concept by providing a strict definition of hypertension that requires more than 50% of BPs to be elevated, starting with the first BP greater than 140 mm Hg systolic and/or greater than 90 mm Hg diastolic ("the 50% rule"). However, this stringent criterion did result in a 12% false-negative rate, in which 3 of 25 patients with gestational hypertension (12%) were classified as normotensive by using the algorithm.
Other methods that are currently being used for HDPs exposure ascertainment uniformly underperform with respect to making accurate diagnoses and classification, thus raising concerns about their use for research. For example, Geller et al 4 found that the use of ICD codes specific for subtypes of preeclampsia had a positive predictive value of only 54%, with coding errors found in as many as one-third of the charts reviewed. Maternal recall (self-report) using a validated survey can be a useful tool. However, as with all tools reliant on subjective memory, it is also susceptible to misclassification bias, especially many years after delivery.
14 In addition, this method relies on contacting women directly, an approach that may not be feasible for all study populations. Finally, some large national obstetric registries are based on data derived from limited chart abstractions performed at hospital discharge, birth certificate data, or discharge codes. 22, 23 These databases have the advantage of including an entire population, but often the information gathered is general, and may not reliably assess Values indicate number of women with a particular diagnosis.
the specific exposure of interest. The algorithm-based approach has several advantages over these alternatives, including that this method (1) compares favorably to physician-made diagnoses; (2) allows HDPs exposure ascertainment on the basis of clinical criteria; (3) facilitates data gathering by trained abstractors other than physicians as well as standardized interpretation; and (4) limits personal biases, which may be introduced when evaluating large data sets accessed by multiple medical professionals. In addition to large epidemiological studies, this electronic algorithm, with minimal modifications, may be a useful tool to identify a particular HDPs phenotype in large research data sets. 24 The main strength of our study is the improved sensitivity of the algorithm to accurately assign HDPs exposure status as compared with previously reported methods that are based on codes, large national registries, or maternal recall. As HDPs definitions have changed multiple times in the past decades, we have also validated our algorithm using a contemporary cohort of women who delivered between January 1, 2012 and December 3, 2015. The misclassifications by our algorithm were manually reviewed, with the following findings: One woman who met criteria for preeclampsia via the algorithm based on sustained hypertension and seizure prophylaxis with magnesium sulfate was diagnosed with gestational hypertension by experts. According to current clinical practice, physicians have a lower threshold for initiating seizure prophylaxis than in the past. Consequently, a minor revision of the algorithm (ie, exclusion of magnesium prophylaxis as a diagnostic criterion for preeclampsia) should be considered to include changes in diagnostic criteria of HDPs that have occurred with time. Ten pregnancies that were normotensive per algorithm were diagnosed with either gestational hypertension (n¼5) or preeclampsia (n¼5) by experts. These 10 women did not meet a strict definition of hypertension that requires more than 50% of BPs to be elevated ("the 50% rule"). Finally, we noted that the sensitivity of codes with respect to the diagnosis of gestational hypertension improved with time: 32% for the historical cohort vs 100% for the contemporary cohort, likely reflecting an increased awareness among practicing obstetricians of elevated BPs in pregnancy. However, this improvement in sensitivity of making the diagnosis of gestational hypertension occurred at the expense of a decrease in sensitivity for normotensive pregnancies, with approximately one-third of these pregnancies being misclassified as gestational hypertension. If the ultimate goal of the study were to compare long-term outcomes between normotensive and hypertensive pregnancies, the use of codes and misclassification of normotensive pregnancies as hypertensive pregnancies would decrease our ability to detect differences between the groups.
Our study has limitations. Our algorithm does not include HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, as it was first described in 1982 25 and our study participants delivered between 1976 and 1982. Consequently, relevant laboratory parameters for the diagnosis of HELLP syndrome were not collected, even for the most severe cases. Future studies that will include pregnancies after 1982 should validate and include diagnostic criteria for HELLP syndrome. This algorithm is optimized with a longitudinal dataset. Therefore, it will have a limited applicability for, databases that contain only information from the time of delivery. This may be resolved in future studies as the recent US Preventive Services Task Force Recommendation Statement indicated that all pregnant women should be screened for preeclampsia with serial BP measurements during pregnancy. 26 Furthermore, there is a risk of underreporting HDPs when using only administrative and hospital discharge data for historical cohorts, as shown by the low sensitivities but reasonable specificities of such methods. Continued use of these more conservative and less accurate methods in epidemiological studies of HDPs does not advance the field.
We suggest that a research strategy such as the one described herein for the diagnosis of HDPs is notable because of the following considerations: (1) Such a strategy achieves greater accuracy than does those based on evaluation of diagnostic codes, the latter being susceptible to misdiagnoses, inaccurate diagnoses, and coding errors. (2) This strategy is comparable in accuracy to those that are based on diagnostic evaluation by relevant experts in the field, but is not encumbered by the time-consuming nature and tedious inefficiency of the former approach. Our algorithm requires manual abstraction of the variables into a database when using older paper records. However, with modern electronic medical records (EMRs), BP and laboratory data can be electronically, rather than manually, retrieved. The development of the EMR has been transformative in the practice of medicine for at least 2 main reasons: First, the EMR provides an unprecedented speed and efficiency with which medical data can be both stored and retrieved. Second, the EMR is a readily accessible and usable database for rapidly evolving fields that seek to accelerate the speed with which diagnoses can be made (eg, machine learning) and with which medical knowledge may be advanced (eg, "big data" mining and bioinformatics). This approach, using the validated HDPs criteria presented in this article, will be entirely consistent with the current and appropriate emphasis on devising novel strategies that capitalize on the intrinsic accuracy and efficiency of the EMR in undertaking health care research.
CONCLUSION
This study confirms the accuracy and precision of our electronic algorithm using chartabstracted clinical data for the diagnoses and classification of HDPs as well as its superiority over diagnostic codes in historical cohorts. It serves as a reliable and more efficient alternative to physician chart review and facilitates making HDPs diagnoses for large-scale retrospective studies. Although the association between HDPs and future cardiovascular and renal disease is increasingly recognized, published epidemiological studies assessing these associations used predominantly diagnostic codes or selfreported events, which correlate poorly with the true presence or absence of HDPs. Therefore, medical chart review by medical professionals and HDPs diagnosis assignment using accepted diagnostic criteria remain the gold standard for diagnosis, but this approach is not feasible because of its cost. We have developed an electronic algorithm for HDPs diagnoses on the basis of the clinical data obtained from medical records by trained abstractors that compared favorably with the gold standard of physicianmade diagnoses. According to the 2017 US Preventive Services Task Force Recommendation Statement, 26 all pregnant women should be screened for preeclampsia with serial BP measurements during pregnancy. Our electronic tool will facilitate future epidemiological studies of long-term HDPs outcomes by correctly assigning both the diagnosis and the type of HDPs in women with serial BP measurements. The use of the electronic algorithm may accommodate retrospective diagnoses of HPDs based on new criteria, should these emerge in the future.
Before using the algorithm, investigators should validate the algorithm-based diagnoses in their own data sets, as differences in patient populations (such as demographic characteristics and mode of health care delivery) may affect its performance characteristics.
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